Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
NCT01191008
Last updated date
ABOUT THIS STUDY
The objective of this Investigation is to evaluate the safety and efficacy of long-term
treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse
drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey
period, and whether an additional treatment outcome investigation and/or a post-marketing
clinical study is required in the future will be determined.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patients need to be administered Xalacom® in order to be enrolled in the surveillance.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Patients not administered Xalacom®.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Glaucoma, Ocular HypertensionStudy to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
NCT00402493
- Willingboro, New Jersey
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionNon-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
NCT01012245
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
- Artesia, California
- Atlanta, Georgia
- Atlanta, Georgia
- North Dartmouth, Massachusetts
- Minneapolis, Minnesota
- Durham, North Carolina
- Koebenhavn OE,
- Catania,
- Coimbra,
- Lisboa,
- Mayfair West,
- Madrid,
- Madrid,
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionComparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US
NCT00847483
- Belleflower, California
- Inglewood, California
- San Diego, California
- San Diego, California
- San Francisco, California
- Gainesville, Florida
- Lakeland, Florida
- Ormond Beach, Florida
- Atlanta, Georgia
- Bloomingdale, Illinois
- Evansville, Indiana
- Louisville, Kentucky
- Louisville, Kentucky
- Shreveport, Louisiana
- Bangor, Maine
- Kansas City, Missouri
- Kansas City, Missouri
- Omaha, Nebraska
- Las Vegas, Nevada
- Bloomfield, New Jersey
- Willingboro, New Jersey
- Charlotte, North Carolina
- Winston-Salem, North Carolina
- Streetsboro, Ohio
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Pittsburgh, Pennsylvania
- Charleston, South Carolina
- Charleston, South Carolina
- Charleston, South Carolina
- Maryville, Tennessee
- Memphis, Tennessee
- Dallas, Texas
- El Paso, Texas
- Houston, Texas
- Layton, Utah
- Norfolk, Virginia
- Norfolk, Virginia
- Virginia Beach, Virginia
- Wenatchee, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension | |||
| Official Title | Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan) | |||
| Brief Summary | The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined. | |||
| Detailed Description | All the patients whom an investigator prescribes the first Xalacom® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random. | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | The patients whom an investigator involving A6641056 prescribes the Xalacom® Combination Eye Drops. | |||
| Condition |
| |||
| Intervention | Drug: Latanoprost-timolol maleate fixed combination ophthalmic solution
Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "One drop should be applied to the affected eye(s) once daily". Other Name: Xalacom | |||
| Study Groups/Cohorts | Latan-timolol maleate fixed comb ophthalmic solution
Intervention: Drug: Latanoprost-timolol maleate fixed combination ophthalmic solution | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 661 | |||
| Original Estimated Enrollment | 600 | |||
| Actual Study Completion Date | May 2015 | |||
| Actual Primary Completion Date | May 2015 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender | Not Provided | |||
| Ages | Child, Adult, Older Adult | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01191008 | |||
| Other Study ID Numbers | A6641056 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2017 | |||